中国实用外科杂志2024，Vol.44Issue(10)：1138-1143,6.DOI:10.19538/j.cjps.issn1005-2208.2024.10.12
胃癌免疫治疗获益人群选择
Selection of beneficiaries of immunotherapy for gastric cancer
摘要
Abstract
Currently,the identification of predictive biomarkers for gastric cancer is paramount in effectively screening individuals who would benefit from immunotherapy for this condition.The Programmed Death Receptor Ligand-1(PD-L1)expression score is a widely utilized clinical biomarker for assessing the effectiveness of immunotherapy in gastric cancer.However,there is still a need for further standardization of the measurement platform,assessment indicators,and cutoff values for PD-L1 expression levels.While microsatellite instability(MSI)status,tumor mutational burden(TMB)levels,and EB virus(EBV)infection have demonstrated promising predictive value in certain clinical trials of gastric cancer immunotherapy,extensive clinical studies are necessary for validation.Moreover,POLE/POLD1 mutations,Helicobacter pylori(Hp)infection,and liquid biopsy have introduced new avenues for investigating predictive biomarkers for gastric cancer immunotherapy.Currently,no precise standard exists for the screening of populations that would benefit from immunotherapy for gastric cancer.The joint utilization of multiple predictive indicators,including the PD-L1 expression score,may enhance the accuracy of screening.关键词
胃癌/免疫治疗/免疫检查点抑制剂/预测性生物标记物Key words
gastric cancer/immunotherapy/immune checkpoint inhibitors/predictive biomarker分类
医药卫生引用本文复制引用
王桂华,周颖彬..胃癌免疫治疗获益人群选择[J].中国实用外科杂志,2024,44(10):1138-1143,6.基金项目
湖北省自然科学基金创新群体项目(No.2021CFA006) （No.2021CFA006）
华中科技大学基础研究支持计划项目(No.2023BR036) （No.2023BR036）
